Silibinin ameliorates colitis by inhibiting the activation of NLRP3 inflammasome

• DOI: 10.3760/cma.j.issn.2096-367x.2019.01.015
• Publication Date: 2019-01-25
• Authors: Jiaheng Ma; Hailong Cao; Xue Chen; Rongjuan Zheng; Wenxiao Dong; Sinan Wang; Xiaocang Cao; Bangmao Wang
• Keywords: Silibinin; Occludin

Objective To investigate the efficacy of silibinin on DSS-induced colitis and its regulation for NLRP3 inflammasome.

Methods A total 48 8-week-old C57BL/6 mice were randomly divided into three groups: control group, DSS group respectively. The was fed with normal chow water seven days while treated 2%DSS in drinking 0.2 ml 0.5%CMC by gavage 750 mg/kg dissolved respectively each mouse once a day days. severity colitis, function intestinal barrier activation inflammasome compared among groups.

Results Compared effectively moderated shrink colon[ (5.34 ± 0.14) cm vs. (4.78 0.13) cm, P<0.01] decreased DAI score 5th (6.73 0.72 8.74 0.45, P = 0.02) , alleviated lesion induced DSS. Serum concentration FITC-D significantly lower[ (2.02 0.22) mg/L (4.28 0.55) mg/L, as expression claudin-1 (0.72 0.15 vs.0.04 0.02, P<0.05) occludin (0.52 0.04 0.18 0.01, MUC2 (0.36 0.06 0.07 0.03, up-regulated silibinin. Expressions F4/80, IL-1β IL-6 group. mRNA protein NLRP3, ASC caspase-1 well.

Conclusions Silibinin can inhibit inflammasome, decrease production inflammatory factors protect gut mucosal barrier, indicating protective effects colitis.

Key words: Silibinin; Nucleotide-binding oligomerization domain-like receptor 3; Inflammasome; Colitis